Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Get Free Report) has earned an average recommendation of “Buy” from the nine ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $18.12.
Several equities analysts have commented on LXEO shares. Wall Street Zen raised shares of Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Lexeo Therapeutics in a research report on Tuesday, September 22nd. JPMorgan Chase & Co. reduced their price objective on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Leerink Partners reiterated an “outperform” rating and issued a $15.00 target price on shares of Lexeo Therapeutics in a report on Wednesday, September 23rd. Finally, Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th.
View Our Latest Analysis on Lexeo Therapeutics
Lexeo Therapeutics Stock Performance
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Equities analysts predict that Lexeo Therapeutics will post -1.18 EPS for the current fiscal year.
Institutional Trading of Lexeo Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. Spark Investment Management LLC acquired a new stake in shares of Lexeo Therapeutics during the second quarter worth about $70,000. Frazier Life Sciences Management L.P. boosted its position in shares of Lexeo Therapeutics by 9.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 4,824,725 shares of the company’s stock valued at $22,459,000 after purchasing an additional 400,000 shares during the period. Montanova Capital LLC boosted its position in shares of Lexeo Therapeutics by 410.7% in the 2nd quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock valued at $29,718,000 after purchasing an additional 5,134,200 shares during the period. Wellington Management Group LLP grew its stake in Lexeo Therapeutics by 17.2% during the 2nd quarter. Wellington Management Group LLP now owns 202,383 shares of the company’s stock worth $942,000 after buying an additional 29,680 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new position in Lexeo Therapeutics during the 2nd quarter worth approximately $6,051,500. 60.67% of the stock is currently owned by institutional investors and hedge funds.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for genetic and acquired diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material intended to address underlying disease mechanisms, with programs spanning central nervous system and cardiovascular conditions.
Lexeo’s development portfolio includes investigational therapies for APOE4-associated Alzheimer’s disease, Friedreich’s ataxia, and inherited cardiac disorders such as LMNA-related dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.
Featured Stories
- Five stocks we like better than Lexeo Therapeutics
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
